Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Cell J. 2015 Winter;16(4):416-25. doi: 10.22074/cellj.2015.488. Epub 2015 Jan 13.
Every cell type is characterized by a specific transcriptional profile together with a unique epigenetic landscape. Reprogramming factors such as Oct4, Klf4, Sox2 and c-Myc enable somatic cells to change their transcriptional profile and convert them to pluripotent cells. Small molecules such as BIX-01294, Bay K8644, RG-108 and valproic acid (VPA) are reported as effective molecules for enhancing induction of pluripotency in vitro, however, their effects during in vivo reprogramming are addressed in this experimental study.
In this experimental study, Oct4 expressing lentiviral particles and small molecules BIX-01294, Bay K8644 and RG-108 were injected into the right ventricle of mice brain and VPA was systematically administered as oral gavages. Animals treated with different combinations of small molecules for 7 or 14 days in concomitant with Oct4 exogenous expression were compared for expression of pluripotency markers. Total RNA was isolated from the rims of the injected ventricle and quantitative polymerase chain reaction (PCR) was performed to evaluate the expression of endogenous Oct4, Nanog, c-Myc, klf4 and Sox2 as pluripotency markers, and Pax6 and Sox1 as neural stem cell (NSC) markers.
Results showed that Oct4 exogenous expression for 7 days induced pluripoten- cy slightly as it was detected by significant enhancement in expression of Nanog (p<0.05). Combinatorial administration of Oct4 expressing vector and BIX-01294, Bay K8644 and RG-108 did not affect the expression of pluripotency and NSC markers, but VPA treatment along with Oct4 exogenous expression induced Nanog, Klf4 and c-Myc (p<0.001). VPA treatment before the induction of exogenous Oct4 was more effective and significantly increased the expression of endogenous Oct4, Nanog, Klf4, c-Myc (p<0.01), Pax6 and Sox1 (p<0.001).
These results suggest VPA as the best enhancer of pluripotency among the chemicals tested, especially when applied prior to pluripotency induction by Oct4.
每种细胞类型都具有特定的转录谱和独特的表观遗传景观。Oct4、Klf4、Sox2 和 c-Myc 等重编程因子使体细胞改变其转录谱并将其转化为多能细胞。BIX-01294、Bay K8644、RG-108 和丙戊酸 (VPA) 等小分子被报道为有效分子,可增强体外多能性诱导,但在体内重编程过程中,本实验研究探讨了它们的作用。
在这项实验研究中,Oct4 表达的慢病毒颗粒和小分子 BIX-01294、Bay K8644 和 RG-108 被注射到小鼠大脑的右心室,VPA 作为口服灌胃给予。用不同组合的小分子处理 7 或 14 天,并与外源性 Oct4 表达同时进行,比较多能性标志物的表达。从注射心室边缘分离总 RNA,并进行定量聚合酶链反应 (PCR),以评估内源性 Oct4、Nanog、c-Myc、klf4 和 Sox2 作为多能性标志物的表达,以及 Pax6 和 Sox1 作为神经干细胞 (NSC) 标志物的表达。
结果表明,Oct4 外源性表达 7 天仅轻微诱导多潜能性,因为 Nanog 的表达显著增强(p<0.05)。Oct4 表达载体与 BIX-01294、Bay K8644 和 RG-108 的联合给药不影响多能性和 NSC 标志物的表达,但 VPA 与外源性 Oct4 表达联合治疗诱导 Nanog、Klf4 和 c-Myc(p<0.001)。在诱导外源性 Oct4 之前进行 VPA 治疗更有效,并显著增加内源性 Oct4、Nanog、Klf4、c-Myc(p<0.01)、Pax6 和 Sox1(p<0.001)的表达。
这些结果表明 VPA 是测试的化学物质中最有效的多潜能性增强剂,尤其是在 Oct4 诱导多潜能性之前应用时。